Search
Penicillium roqueforti
go.drugbank.com/drugs/DB10812ApprovedPenicillium roqueforti is a fungus which can provoke allergic reactions. Penicillium roqueforti extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureMeningococcal polysaccharide vaccine group C
go.drugbank.com/drugs/DB13890ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Mixtures: NIMENRIX 0,5 ML IM ENJEKSIYON ICIN TOZ ICEREN FLAKON VE COZUCU ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADETMosunetuzumab
go.drugbank.com/drugs/DB15434ApprovedInvestigational[L42230] It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. … [A249320,A249390] Mosunetuzumab has the potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and unlike CAR-T therapies such as [axicabtagene ciloleucel
Riltozinameran
go.drugbank.com/drugs/DB17095ApprovedInvestigational[L43917] As of November 2022, it is the primary circulating variant of concern according to the World Health Organization. … [L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta).
Elacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[L49334] Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor degrader (SERD) thanks to its ability to block the transcriptional activity of the ER and promote … [A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Fremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment … [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.
Iloprost
go.drugbank.com/drugs/DB01088ApprovedInvestigationalIt is used to treat pulmonary arterial hypertension (PAH) [L50146] and frostbites.[L50151] … Iloprost is an analog of prostacyclin (PGI2; epoprostenol), an endogenous prostanoid mainly produced in the vascular endothelium. It is more stable than prostacyclin, which is short-lived.
Synonyms: (5E)-[3aS,4R,5R,6aS)-5-Hydroxy-4-[(1E)-(3S,4RS)-3-hydroxy-4-methyloct-1-en-6-ynyl]-hexahydropentalen-2(1H)-ylidene]pentanoic acid, (E)-(3aS, 4R, 5R, 6aS)-hexahydro-5-hydroxy-4-[(E)-(3S,4RS) 3-hydroxy-4-methyl-1-octen-6-ynyl]-Δ2(1H),Δ-pentalenevaleric acidBicalutamide
go.drugbank.com/drugs/DB01128ApprovedInvestigationalIt is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Apomorphine
go.drugbank.com/drugs/DB00714ApprovedInvestigationalApomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol, (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diolSevoflurane
go.drugbank.com/drugs/DB01236ApprovedInvestigationalVet approvedSevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. … Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway.